Eileen Holmes

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Evandro de Azambuja, Andrew Holmes, Martine Piccart et al. · The Lancet Oncology · 2014 · 452 citations

Survival Outcomes, Breast Oncology, Medicine +7

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart, Eileen Holmes, José Baselga et al. · Journal of Clinical Oncology · 2015 · 370 citations · Full text

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

S. Loibl, Ian J. Majewski, Valentina Guarneri et al. · Annals of Oncology · 2016 · 225 citations · Full text

Breast Oncology, Medicine, Pathology +8

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja et al. · The Lancet Oncology · 2013 · 207 citations

Breast Oncology, Medicine, Hera Trial +8

¹⁸F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Géraldine Gebhart, Cristina Gámez‐Cenzano, Eileen Holmes et al. · Journal of Nuclear Medicine · 2013 · 157 citations · Full text